inClinico
Multimodal AI platform that forecasts the probability of success of individual clinical trials and scores alternative trial designs before implementation.
Find alternatives to inClinico
What it does
- Drug discovery
- Data analysis
Features 5
- Scoring of custom trialsCompares planned clinical trial designs and optimizes them for success.
- Historical and ongoing trials databaseDatabase of clinical trials sortable by probability of success for researching successful designs.
- Clinical Trial Outcome ScoresAnalyzes performance of individual trials with simple data-driven probability-of-success metrics.
- Comprehensive Report GenerationCustomized reports with probability of success and feature impacts built from OMICs, structure, protocol and literature inputs.
- Protocol design simulationSimulates alternative clinical protocol designs and reports their impact on probability of success.
Sources
- Pricing
-
Official documentation · 3 Sep 2026
Demo request required for access and pricing; targeted at buy-side analysts, BD&L executives and clinical developers.
- Constraints
-
Official documentation · 2 Oct 2026
Derived from the security facts on this page, from the same source.
- Security
-
Official documentation · 2 Oct 2026
Company-wide Security & IT page covering client data and IP across engagements, applied to all listed products (page names none individually). ISO 27001 refers to the ISMS. Residency is client-chosen cloud servers, recorded as custom. Training, ZDR, DPA not stated.
- Sold within
-
Official documentation · 15 Sep 2026
pharma.ai/inclinico (already cited official-docs elsewhere on this record); no packaging restriction stated.
- Modalities
-
Official documentation · 1 Oct 2026
Page: 'customized reports with PoS and feature impacts on probabilities generated on inputs from OMICs data, drug structure, trial protocol, preclinical data, and publications, grants, and patents'.
- Intended for
-
Named segments: "Buy-side analysts at pharma-focused funds", "BD&L executives" doing "Mergers and Acquisitions, licensing and partnerships" at pharma companies (enterprise), and "Clinical researchers" doing trial design (researcher).
Also from Insilico Medicine
-
Pharma.AI Platform
End-to-end generative-AI platform spanning target discovery, molecular design and clinical-trial risk assessment for pharmaceutical research.
-
PandaOmics Platform
AI platform for therapeutic target identification, biomarker discovery, indication prioritization and drug repurposing over a multi-omics knowledge base; also answers literature-review questions through ChatPandaGPT.
-
PandaOmics Box Hardware
On-premise AI appliance running PandaOmics target and biomarker discovery locally with no external data transmission, sold in Server and Desktop editions.
-
Chemistry42 Platform
Generative small-molecule design platform combining de novo generation with physics-based methods, retrosynthesis, ADMET profiling and custom model training.
-
Biology42: Generative Biologics Platform
AI platform for de novo design and multi-property optimization of peptides, nanobodies and antibodies against specified targets and epitopes.
-
Science42: DORA Application
AI research writing assistant that drafts structured, cited papers, reviews, grant proposals and abstracts against biomedical databases such as PubMed and bioRxiv.
-
MMAI Gym Platform
Foundation-model training and benchmarking platform that fine-tunes a customer's own LLM on Insilico's proprietary pharma reasoning datasets and validates results in its automation lab.
Open Insilico Medicine in the directory
Something wrong here? Send a correction — quote this product id: insilico-medicine-inclinico.